Kolkata, India: Bharat Biotech — India’s first indigenous COVID-19 vaccine maker — stated today that CHIRON BEHRING Vaccines, Ankleshwar Gujarat, a fully owned subsidiary of Bharat Biotech, has quickly ramped up additional manufacturing capacity for COVAXIN.
The company will now produce an additional 200 million doses of COVAXIN® per year in GMP facilities that are currently in operation for the manufacturing of vaccines based on the Inactivated Vero Cell Platform Technology, all while adhering to strict GMP and biosafety standards, as per media reports.
Product availability in Ankleshwar will begin in the fourth quarter of 2021.
Bharat Biotech has previously set up various production lines at its Hyderabad and Bengaluru locations, and now Chiron Behring has joined the list of high-security BSL rated GMP facilities necessary to make COVAXIN®.
With its own established sites specialized for producing inactivated viral vaccines under the highest levels of biosafety, this effectively takes the quantities up to 1 billion doses per year.
India tumbles into Covid hell
The vaccine production boost comes at the heels of a tremendous outbreak of the novel coronavirus that has pushed the nation’s already-impoverished healthcare sector on the brink of collapse.
However, India’s daily recovery has been outnumbering the daily new cases for the seventh consecutive day.
3,69,077 recoveries were registered in the last 24 hours, taking India’s cumulative recoveries to 2,23,55,440 today.
The National Recovery Rate has grown further to touch 86.74%. Ten states account for 75.11% of the new recoveries.
In another positive development, India records less than 3 lakh new cases for four consecutive days now.